Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage Report: A Breakthrough Year for Unmet Diseases

EP Vantage Breakthrough Year for Unmet Diseases




  Download Report

This latest report from EP Vantage: A Breakthrough Year for Unmet Diseases shows since the FDA's breakthrough therapy designation (BTD) was put into effect in July of 2012, pharma and biotech companies have certainly taken note.

The list of 30 disclosed BTD projects so far reveals that the vast majority have favoured big pharma and big biotech despite the FDA's promise to provide assistance on clinical trial design and guidance on development, which were aimed at the small, cash-strapped biotechs.

Key findings in the EP Vantage: A Breakthrough Year for Unmet Diseases:

  • No fewer than 141 BTDs have been applied for, of which, 37 have been granted
  • Three breakthrough-designated products have received US approval: Roche's Gazyva; J&J/Pharmacyclics' Imbruvica; Gilead's Sovaldi
  • Large companies in phase III projects dominate the disclosed breakthrough therapy projects to date
  • The various accelerated pathways have become a part of the product development landscape

Download Report

Press Release

Related Reports: 

EP Vantage FDA Approval Rates 2013

EP Vantage Medtech Half-Year Review 2013

EP Vantage Pharma Half-Year Review 2013